Department of Neurosurgery, Faculty of Medicine, Suleyman Demirel University, Isparta, Turkey.
Neuroscience Research Center, Suleyman Demirel University, Isparta, Turkey.
Neurotox Res. 2019 May;35(4):797-808. doi: 10.1007/s12640-019-0009-5. Epub 2019 Feb 22.
The rate of mitosis of cancer cells is significantly higher than normal primary cells with increased metabolic needs, which in turn enhances the generation of reactive oxygen species (ROS) production. Higher ROS production is known to increase cancer cell dependence on ROS scavenging systems to counteract the increased ROS. Therapeutic options which selectively modulate the levels of intracellular ROS in cancers are likely candidates for drug discovery. Docetaxel (DTX) has demonstrated antitumor activity in preclinical and clinical studies. It is thought that DTX induces cell death through excessive ROS production and increased Ca entry. The Ca permeable TRPM2 channel is activated by ROS. Selenium (Se) has been previously used to stimulate apoptosis for the treatment of glioblastoma cells resistant to DTX. However, the potential mechanism(s) of the additive effect of DTX on TRPM2 channels in cancer cells remains unclear. The aim of this study was to evaluate the effect of combination therapy of DTX and Se on activation of TRPM2 in DBTRG glioblastoma cells. DBTRG cells were divided into four treatment groups: control, DTX (10 nM for 10 h), Se (1 μM for 10 h), and DTX+Se. Our study showed that apoptosis (Annexin V and propidium iodide), mitochondrial membrane depolarization (JC1), and ROS production levels were increased in DBTRG cells following treatment with Se and DTX respectively. Cell number and viability, and the levels of apoptosis, JC1, ROS, and [Ca], induced by DTX, were further increased following addition of Se. We also observed an additive increase in the activation of the NAD-dependent DNA repair enzyme poly (ADP-ribose) polymerase-1 (PARP-1) activity, which was accompanied by a decline in its essential substrate NAD. As well, the Se- and DTX-induced increases in intracellular Ca florescence intensity were decreased following treatment with the TRPM2 antagonist N-(p-amylcinnamoyl) anthranilic acid (ACA). Therefore, combination therapy with Se and DTX may represent an effective strategy for the treatment of glioblastoma cells and may be associated with TRPM2-mediated increases in oxidative stress and [Ca].
癌细胞的有丝分裂率明显高于具有增加的代谢需求的正常原代细胞,这反过来又增强了活性氧物种(ROS)的产生。已知较高的 ROS 产生会增加癌细胞对 ROS 清除系统的依赖性,以抵消增加的 ROS。选择性调节癌细胞内 ROS 水平的治疗选择可能是药物发现的候选者。多西紫杉醇(DTX)在临床前和临床研究中表现出抗肿瘤活性。据认为,DTX 通过过度产生 ROS 和增加 Ca 内流诱导细胞死亡。ROS 激活钙渗透性 TRPM2 通道。硒(Se)以前曾用于刺激凋亡,以治疗对 DTX 耐药的胶质母细胞瘤细胞。然而,DTX 对癌细胞中 TRPM2 通道的附加作用的潜在机制尚不清楚。本研究旨在评估 DTX 和 Se 的联合治疗对 DBTRG 胶质母细胞瘤细胞中 TRPM2 激活的影响。DBTRG 细胞分为四组治疗:对照组、DTX(10 nM 处理 10 小时)、Se(1 μM 处理 10 小时)和 DTX+Se。我们的研究表明,在用 Se 和 DTX 处理后,DBTRG 细胞中的细胞凋亡(Annexin V 和碘化丙啶)、线粒体膜去极化(JC1)和 ROS 产生水平分别增加。在用 Se 处理后,DTX 诱导的细胞数和活力以及凋亡、JC1、ROS 和 [Ca]水平进一步增加。我们还观察到 NAD 依赖性 DNA 修复酶聚(ADP-核糖)聚合酶-1(PARP-1)活性的加性增加,这伴随着其必需底物 NAD 的减少。此外,在用 TRPM2 拮抗剂 N-(对氨基肉桂酰)邻苯二甲酰亚胺酸(ACA)处理后,Se 和 DTX 诱导的细胞内 Ca 荧光强度增加减少。因此,Se 和 DTX 的联合治疗可能代表治疗胶质母细胞瘤细胞的有效策略,并且可能与 TRPM2 介导的氧化应激和 [Ca]增加有关。
Biomark Res. 2024-12-4
Turk J Biol. 2023-8-10
Front Physiol. 2023-7-27
Int J Mol Sci. 2023-1-28
Pharmaceutics. 2022-12-28
Antioxidants (Basel). 2023-1-6
Biol Trace Elem Res. 2023-8
Int J Pharm. 2018-3-16
Artif Cells Nanomed Biotechnol. 2018-3-8
Front Physiol. 2017-12-13
CA Cancer J Clin. 2018-1-4
J Trace Elem Med Biol. 2017-4-29
J Recept Signal Transduct Res. 2017-12